Although agents targeting hormone receptors and HER2 can be used to treat hormone receptor-positive and HER2-positive types of breast cancer, these agents are ineffective against TNBC because of the absence of the targeted receptors (ER, PR, and HER2) [7, 8]. This evidence concerns the gene ESR1 and breast cancer.